The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx’s existing and future AI initiatives
The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company’s upcoming Co-Dx™ PCR platform and other Co-Dx IP
The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures
Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform
Co-Diagnostics announced that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company’s customer and distributor update today at AACC.
Co-Diagnostics announced that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors.
Co-Diagnostics announced that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.
Co-Diagnostics announced that CoSara Diagnostics has received clearance by the CDSCO in India to manufacture and sell its SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic.
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board